161 related articles for article (PubMed ID: 15657587)
1. Large remnant 131I ablation as an alternative to completion/total thyroidectomy in the treatment of well-differentiated thyroid cancer.
Leblanc G; Tabah R; Liberman M; Sampalis J; Younan R; How J
Surgery; 2004 Dec; 136(6):1275-80. PubMed ID: 15657587
[TBL] [Abstract][Full Text] [Related]
2. Hürthle cell carcinoma: a clinicopathological study of thirteen cases.
Ozlem Küçük N; Kulak H; Tokmak E; Tar P; Ibiş E; Aras G
Nucl Med Commun; 2006 Apr; 27(4):377-9. PubMed ID: 16531925
[TBL] [Abstract][Full Text] [Related]
3. Prognostic factors in well-differentiated thyroid carcinoma in patients treated and followed in the same institution.
Cappelli C; Pirola I; Braga M; De Martino E; Morassi ML; Gandossi E; Mattanza C; Balzano R; Castellano M; Rosei EA
Ann Ital Chir; 2006; 77(2):107-13. PubMed ID: 17147082
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant external-beam radiotherapy in patients with high-risk well-differentiated thyroid cancer.
Chen PV; Osborne R; Ahn E; Avitia S; Juillard G
Ear Nose Throat J; 2009 Jul; 88(7):E01. PubMed ID: 19623515
[TBL] [Abstract][Full Text] [Related]
5. Hurthle cell neoplasm of the thyroid gland.
Ahmed M; Bin Yousef H; Greer W; Faraz H; Al Sobhi S; Al Zahrani A; Raef H; Al Ghamdi A; Al Kadhi Y; Al Dayel F
ANZ J Surg; 2008 Mar; 78(3):139-43. PubMed ID: 18269475
[TBL] [Abstract][Full Text] [Related]
6. Treatment for microcarcinoma of the thyroid--clinical experience.
Küçük NO; Tari P; Tokmak E; Aras G
Clin Nucl Med; 2007 Apr; 32(4):279-81. PubMed ID: 17413573
[TBL] [Abstract][Full Text] [Related]
7. A prospective clinical trial to assess the efficacy of radioiodine ablation as an alternative to completion thyroidectomy in patients with differentiated thyroid cancer undergoing sub-total thyroidectomy.
Bal CS; Kumar A; Chandra P; Dwivedi SN; Pant GS
Acta Oncol; 2006; 45(8):1067-72. PubMed ID: 17118841
[TBL] [Abstract][Full Text] [Related]
8. Cumulative doses of adjunct 131I treatment depend on location of residual thyroid tissue after total thyroidectomy in differentiated thyroid cancer.
Saint-Vil D; Emran MA; Lambert R; Alos N; Turpin S; Huot C
J Pediatr Surg; 2007 May; 42(5):853-6. PubMed ID: 17502198
[TBL] [Abstract][Full Text] [Related]
9. AMES prognostic index and extent of thyroidectomy for well-differentiated thyroid cancer in the United States.
Haigh PI; Urbach DR; Rotstein LE
Surgery; 2004 Sep; 136(3):609-16. PubMed ID: 15349109
[TBL] [Abstract][Full Text] [Related]
10. High recurrent rate of multicentric papillary thyroid carcinoma.
Lin JD; Chao TC; Hsueh C; Kuo SF
Ann Surg Oncol; 2009 Sep; 16(9):2609-16. PubMed ID: 19533244
[TBL] [Abstract][Full Text] [Related]
11. [Radioiodine therapy in differentiated thyroid gland carcinoma].
Schicha H; Dietlein M
Zentralbl Chir; 1997; 122(4):266-73. PubMed ID: 9221637
[TBL] [Abstract][Full Text] [Related]
12. Management of follicular and Hürthle cell neoplasms of the thyroid gland.
McHenry CR; Sandoval BA
Surg Oncol Clin N Am; 1998 Oct; 7(4):893-910. PubMed ID: 9735140
[TBL] [Abstract][Full Text] [Related]
13. Conservative management of patients with intrathyroidal well-differentiated follicular thyroid carcinoma.
Saadi H; Kleidermacher P; Esselstyn C
Surgery; 2001 Jul; 130(1):30-5. PubMed ID: 11436009
[TBL] [Abstract][Full Text] [Related]
14. Ablation of the thyroid remnant and 131I dose in differentiated thyroid cancer.
Doi SA; Woodhouse NJ
Clin Endocrinol (Oxf); 2000 Jun; 52(6):765-73. PubMed ID: 10848882
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic outcomes of papillary thyroid carcinomas with tumors more advanced than T1N0M0.
Lin JD; Lin KJ; Chao TC; Hseuh C; Tsang NM
Radiother Oncol; 2008 Oct; 89(1):97-104. PubMed ID: 18534700
[TBL] [Abstract][Full Text] [Related]
16. Hurthle cell tumor.
Chen HY; Benjamin LB; Chen MF
Int Surg; 1996; 81(2):168-70. PubMed ID: 8912085
[TBL] [Abstract][Full Text] [Related]
17. Incidence of radiation thyroiditis and thyroid remnant ablation success rates following 1110 MBq (30 mCi) and 3700 MBq (100 mCi) post-surgical 131I ablation therapy for differentiated thyroid carcinoma.
Cherk MH; Kalff V; Yap KS; Bailey M; Topliss D; Kelly MJ
Clin Endocrinol (Oxf); 2008 Dec; 69(6):957-62. PubMed ID: 18419785
[TBL] [Abstract][Full Text] [Related]
18. Differentiated thyroid carcinoma with distant metastases at presentation: prognostic factors and outcome.
Haq M; Harmer C
Clin Endocrinol (Oxf); 2005 Jul; 63(1):87-93. PubMed ID: 15963067
[TBL] [Abstract][Full Text] [Related]
19. [Differentiated thyroid cancers].
Gorgone S; Campennì A; Calbo E; Catalfamo A; Sciglitano P; Sofia L; Niceta M; Borzì R; Calbo L
G Chir; 2009; 30(1-2):26-9. PubMed ID: 19272228
[TBL] [Abstract][Full Text] [Related]
20. Preoperative undetectable serum thyroglobulin in differentiated thyroid carcinoma: incidence, causes and management strategy.
Giovanella L; Ceriani L; Ghelfo A; Maffioli M; Keller F
Clin Endocrinol (Oxf); 2007 Oct; 67(4):547-51. PubMed ID: 17561976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
